{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Progression free survival was defined as the absence of disease progression or death from any cause at the 3 year assessment time point.","groups":[{"description":"Denosumab: 120mg of Denosumab will be administered subcutaneously once every 4 weeks","id":"OG000","title":"Denosumab"}],"paramType":"NUMBER","populationDescription":"The analysis includes participants with available progression free survival follow up data at the 3 year assessment time point.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Proportion of Participants With Progression Free Survival at 3 Years","type":"SECONDARY","unitOfMeasure":"participants"}